11/28/25, 8:25 AM US RAC Review Questions RAPS Modules Exam Questions & Answers | 100% Verified solutions |Questions with Correct Answers…
US RAC Review Questions RAPS Modules Exam
Questions & Answers | 100% Verified solutions
|Questions with Correct Answers 2025 latest
update!!
Save
Terms in this set (90)
In which situation is an C) You intend to collect blood samples from subjects
IND not required? to look for biomarkers or pharmacogenetic
information
A) You intend to conduct a
clinical trial with an
investigational new drug
B) You intend to conduct a
clinical trial with an
approved drug to support
a marketing application
for a new indication
C) You intend to collect
blood samples from
subjects to look for
biomarkers or
pharmacogenetic
information
D) You intend to conduct a
clinical trial using 2 of your
approved drugs in a new
combination
https://quizlet.com/1114157050/us-rac-review-questions-raps-modules-exam-questions-answers-100-verified-solutions-questions-with-correct-answer… 1/52
,11/28/25, 8:25 AM US RAC Review Questions RAPS Modules Exam Questions & Answers | 100% Verified solutions |Questions with Correct Answers…
In the clinical B) Single dose escalation PK study in healthy
development plan for an volunteers
investigational
antihypertensive drug,
which of the following
studies would typically be
conducted first:
A) 1 month repeat dose
toxicology study
B) Single dose escalation
PK study in healthy
volunteers
C) Multiple dose PK study
in healthy volunteers
D) Single dose escalation
study in hypertensive
patients
A sponsor must report an B) to FDA and investigators within 7 calendar days
unexpected, fatal or life-
threatening experience
believed to be associated
with an unapproved
drug/biologic:
A) to FDA, investigators
and IRBs within 7 calendar
days
B) to FDA and
investigators within 7
calendar days
C) to FDA within 14
calendar days
D) to FDA and
investigators within 7
working days
https://quizlet.com/1114157050/us-rac-review-questions-raps-modules-exam-questions-answers-100-verified-solutions-questions-with-correct-answer… 2/52
,11/28/25, 8:25 AM US RAC Review Questions RAPS Modules Exam Questions & Answers | 100% Verified solutions |Questions with Correct Answers…
Which of the following is a D) Phase III pivotal study
covered study as defined
under Financial Disclosure
regulations:
A) Phase I dose escalation
study
B) Phase I/II
Pharmacokinetic Study
C) A large open label
safety study conducted at
a large number of study
sites
D) Phase III pivotal study
https://quizlet.com/1114157050/us-rac-review-questions-raps-modules-exam-questions-answers-100-verified-solutions-questions-with-correct-answer… 3/52
, 11/28/25, 8:25 AM US RAC Review Questions RAPS Modules Exam Questions & Answers | 100% Verified solutions |Questions with Correct Answers…
Your company is A) Request Special Protocol Assessment
developing a product to
treat a serious and life
threatening disease. A
clinically meaningful, well
established primary
endpoint will be used in
the pivotal studies. Which
regulatory strategy might
you select prior to
commencing Phase 3
studies?
A) Request Special
Protocol Assessment
B) Request Fast Track
Designation
C) Request Priority Review
D) Approval under
Subpart H, Accelerated
Approval of New Drugs
for Serious or Life
Threatening Illnesses
https://quizlet.com/1114157050/us-rac-review-questions-raps-modules-exam-questions-answers-100-verified-solutions-questions-with-correct-answer… 4/52
US RAC Review Questions RAPS Modules Exam
Questions & Answers | 100% Verified solutions
|Questions with Correct Answers 2025 latest
update!!
Save
Terms in this set (90)
In which situation is an C) You intend to collect blood samples from subjects
IND not required? to look for biomarkers or pharmacogenetic
information
A) You intend to conduct a
clinical trial with an
investigational new drug
B) You intend to conduct a
clinical trial with an
approved drug to support
a marketing application
for a new indication
C) You intend to collect
blood samples from
subjects to look for
biomarkers or
pharmacogenetic
information
D) You intend to conduct a
clinical trial using 2 of your
approved drugs in a new
combination
https://quizlet.com/1114157050/us-rac-review-questions-raps-modules-exam-questions-answers-100-verified-solutions-questions-with-correct-answer… 1/52
,11/28/25, 8:25 AM US RAC Review Questions RAPS Modules Exam Questions & Answers | 100% Verified solutions |Questions with Correct Answers…
In the clinical B) Single dose escalation PK study in healthy
development plan for an volunteers
investigational
antihypertensive drug,
which of the following
studies would typically be
conducted first:
A) 1 month repeat dose
toxicology study
B) Single dose escalation
PK study in healthy
volunteers
C) Multiple dose PK study
in healthy volunteers
D) Single dose escalation
study in hypertensive
patients
A sponsor must report an B) to FDA and investigators within 7 calendar days
unexpected, fatal or life-
threatening experience
believed to be associated
with an unapproved
drug/biologic:
A) to FDA, investigators
and IRBs within 7 calendar
days
B) to FDA and
investigators within 7
calendar days
C) to FDA within 14
calendar days
D) to FDA and
investigators within 7
working days
https://quizlet.com/1114157050/us-rac-review-questions-raps-modules-exam-questions-answers-100-verified-solutions-questions-with-correct-answer… 2/52
,11/28/25, 8:25 AM US RAC Review Questions RAPS Modules Exam Questions & Answers | 100% Verified solutions |Questions with Correct Answers…
Which of the following is a D) Phase III pivotal study
covered study as defined
under Financial Disclosure
regulations:
A) Phase I dose escalation
study
B) Phase I/II
Pharmacokinetic Study
C) A large open label
safety study conducted at
a large number of study
sites
D) Phase III pivotal study
https://quizlet.com/1114157050/us-rac-review-questions-raps-modules-exam-questions-answers-100-verified-solutions-questions-with-correct-answer… 3/52
, 11/28/25, 8:25 AM US RAC Review Questions RAPS Modules Exam Questions & Answers | 100% Verified solutions |Questions with Correct Answers…
Your company is A) Request Special Protocol Assessment
developing a product to
treat a serious and life
threatening disease. A
clinically meaningful, well
established primary
endpoint will be used in
the pivotal studies. Which
regulatory strategy might
you select prior to
commencing Phase 3
studies?
A) Request Special
Protocol Assessment
B) Request Fast Track
Designation
C) Request Priority Review
D) Approval under
Subpart H, Accelerated
Approval of New Drugs
for Serious or Life
Threatening Illnesses
https://quizlet.com/1114157050/us-rac-review-questions-raps-modules-exam-questions-answers-100-verified-solutions-questions-with-correct-answer… 4/52
